FOXO4-DRI 10mg (CAS 2460055-10-9) is a high-purity senolytic peptide API, produced under strict GMP standards to ensure ≥98% purity and reliable biological activity. As a synthetic peptide, it specifically blocks the FOXO4-p53 interaction, selectively inducing apoptosis in senescent cells without harming healthy cells.
This API excels in senescent cell clearance, reversing age-related tissue dysfunction in preclinical studies. It supports research on anti-aging, age-related diseases (e.g., osteoarthritis, fibrosis), and regenerative medicine, making it ideal for pharmaceutical manufacturers and research institutions focused on geroscience.
Its water-soluble, easy-to-reconstitute form enhances application convenience, while its targeted senolytic effect reduces non-specific interference. This raw material provides a valuable foundation for developing anti-aging formulations or advancing senescence-related research.
